Title : Rationale for combination therapy in myelofibrosis.

Pub. Date : 2014 Jun

PMID : 25189730






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The rationale of combination of danazol or lenalidomide with ruxolitinib is mainly based on mitigation of anti-JAK2-mediated myelosuppression. Lenalidomide Janus kinase 2 Homo sapiens